Comments
Loading...
Revive Therapeutics Analyst Ratings and Price Targets | OTC:RVVTF | Benzinga
Revive Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Revive Therapeutics Corp from these most-recent analyst ratings.
Analyst Ratings for Revive Therapeutics
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Revive Therapeutics (RVVTF) stock?
There is no price target for Revive Therapeutics
What is the most recent analyst rating for Revive Therapeutics (RVVTF)?
There is no analyst for Revive Therapeutics
When was the last upgrade for Revive Therapeutics (RVVTF)?
There is no last upgrade for Revive Therapeutics
When was the last downgrade for Revive Therapeutics (RVVTF)?
There is no last downgrade for Revive Therapeutics.
When is the next analyst rating going to be posted or updated for Revive Therapeutics (RVVTF)?
There is no next analyst rating for Revive Therapeutics.
Is the Analyst Rating Revive Therapeutics (RVVTF) correct?
There is no next analyst rating for Revive Therapeutics.
Browse analyst ratings and price targets on all stocks.
